A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes (EDCOS)

Boehringer Ingelheim

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Empagliflozin

Study type: Observational

Funder types: Industry

Identifiers

NCT04098575

1245-0198

Details and patient eligibility

About

Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals

Enrollment: 9,571 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at least one inpatient T2DM diagnosis (ICD E11)
• At least one prescription of an empagliflozin-containing antidiabetic drug: Jardiance® (Empagliflozin, ATC A10BK03, former A10BX12) or Synjardy® (Empagliflozin/ Met¬for¬min, ATC A10BD20)

Exclusion criteria

• Any diagnosis of T1DM

Trial design

9,571 participants in 3 patient groups

Patients receiving Empagliflozin until mid Sep 2015

Description:

Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1

Treatment:

Drug: Empagliflozin

Patients receiving Empagliflozin until CV Label Change time

Description:

Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2

Treatment:

Drug: Empagliflozin

Patients receiving Empagliflozin until last available data cut

Description:

Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3

Treatment:

Drug: Empagliflozin